Iluvien, an intravitreal implant for the treatment of chronic diabetic macula oedema (DME) developed by Alimera Sciences, has been granted market authorization by the Austrian Agency for Health and Food Safety.
Iluvien, an intravitreal implant for the treatment of chronic diabetic macula oedema (DME) developed by Alimera Sciences, has been granted market authorization by the Austrian Agency for Health and Food Safety.
Iluvien is a sustained release intravitreal implant inserted into the back of the eye. It delivers sub-microgram levels of fluocinolone acetonide (FAc) and can be effective for up to 36 months.
The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK completed the Decentralized Regulatory Procedure (DCP) and issued a positive outcome to Iluvien. Other countries delivering a positive outcome included Austria, France, Germany, Italy, Spain and Portugal. Additional Concerned Member State (CMS) marketing authorizations are expected later this year.
Dan Myers, president and chief executive officer at Alimera Sciences, said, “We are excited to receive this marketing authorization and pleased that DME patients in Austria will have this therapy available to them. We look forward to receiving the additional expected approvals from the U.K. and other Concerned Member States as we continue on track with our commercialization plans in the EU.”
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
2 Commerce Drive
Cranbury, NJ 08512